BACKGROUND: By inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase, statins not only reduce cholesterol biosynthesis but also decrease the formation of isoprenoids, which are important for mediating signaling through the Rho-associated coiled-coil containing protein kinase (ROCK) pathway. Increased ROCK activity has been implicated in endothelial dysfunction and vascular inflammation. We hypothesize that ezetimibe, which inhibits intestinal cholesterol absorption, may not exert similar cholesterol-independent or pleiotropic effects of statins and, when used with a lower dose of statin, have less effect on ROCK activity than a higher dose of statin. METHODS AND RESULTS: In a prospective, randomized, observer-blinded study, we treated 60 dyslipidemic subjects without cardiovascular disease withsimvastatin 40 mg/d, simvastatin/ezetimibe 10/10 mg/d, or placebo tabletsfor 28 days (n=20 in each arm). We evaluated baseline demographics and lipid levels, ROCK activity, C-reactive protein, and flow-mediated dilation before and after treatment. Compared with the placebo group, both treatment regimens decreased low-density lipoprotein cholesterol by 38% and C-reactive protein by 38% to 40% after 28 days (P<0.01 for both compared with placebo). Although the low-density lipoprotein cholesterol and C-reactive protein reductions were comparable with either lipid-lowering regimen, only simvastatin 40 mg reduced ROCK activity and improved flow-mediated dilation (P<0.01 for both compared with baseline). Reduction in ROCK activity with simvastatin 40 mg remained significant even after controlling for changes in low-density lipoprotein cholesterol (P=0.01) and correlated with improvement in flow-mediated dilation (R(2)=-0.78, P<0.01). No correlation was found between changes in flow-mediated dilation and changes in low-density lipoprotein cholesterol or C-reactive protein. CONCLUSIONS: These results indicate that high-dose statin monotherapy exerts greater effects on ROCK activity and endothelial function, but not on C-reactive protein, than low-dose statin plus ezetimibe. These findings provide additional evidence of statin benefits beyond cholesterol lowering.
RCT Entities:
BACKGROUND: By inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase, statins not only reduce cholesterol biosynthesis but also decrease the formation of isoprenoids, which are important for mediating signaling through the Rho-associated coiled-coil containing protein kinase (ROCK) pathway. Increased ROCK activity has been implicated in endothelial dysfunction and vascular inflammation. We hypothesize that ezetimibe, which inhibits intestinal cholesterol absorption, may not exert similar cholesterol-independent or pleiotropic effects of statins and, when used with a lower dose of statin, have less effect on ROCK activity than a higher dose of statin. METHODS AND RESULTS: In a prospective, randomized, observer-blinded study, we treated 60 dyslipidemic subjects without cardiovascular disease with simvastatin 40 mg/d, simvastatin/ezetimibe 10/10 mg/d, or placebo tablets for 28 days (n=20 in each arm). We evaluated baseline demographics and lipid levels, ROCK activity, C-reactive protein, and flow-mediated dilation before and after treatment. Compared with the placebo group, both treatment regimens decreased low-density lipoprotein cholesterol by 38% and C-reactive protein by 38% to 40% after 28 days (P<0.01 for both compared with placebo). Although the low-density lipoprotein cholesterol and C-reactive protein reductions were comparable with either lipid-lowering regimen, only simvastatin 40 mg reduced ROCK activity and improved flow-mediated dilation (P<0.01 for both compared with baseline). Reduction in ROCK activity with simvastatin 40 mg remained significant even after controlling for changes in low-density lipoprotein cholesterol (P=0.01) and correlated with improvement in flow-mediated dilation (R(2)=-0.78, P<0.01). No correlation was found between changes in flow-mediated dilation and changes in low-density lipoprotein cholesterol or C-reactive protein. CONCLUSIONS: These results indicate that high-dose statin monotherapy exerts greater effects on ROCK activity and endothelial function, but not on C-reactive protein, than low-dose statin plus ezetimibe. These findings provide additional evidence of statin benefits beyond cholesterol lowering.
Authors: N Sawada; H Itoh; K Ueyama; J Yamashita; K Doi; T H Chun; M Inoue; K Masatsugu; T Saito; Y Fukunaga; S Sakaguchi; H Arai; N Ohno; M Komeda; K Nakao Journal: Circulation Date: 2000-05-02 Impact factor: 29.690
Authors: S Dimmeler; A Aicher; M Vasa; C Mildner-Rihm; K Adler; M Tiemann; H Rütten; S Fichtlscherer; H Martin; A M Zeiher Journal: J Clin Invest Date: 2001-08 Impact factor: 14.808
Authors: U Laufs; M Endres; N Stagliano; S Amin-Hanjani; D S Chui; S X Yang; T Simoncini; M Yamada; E Rabkin; P G Allen; P L Huang; M Böhm; F J Schoen; M A Moskowitz; J K Liao Journal: J Clin Invest Date: 2000-07 Impact factor: 14.808
Authors: Weiguo Chen; Rajesh Sharma; Alicia N Rizzo; Jessica H Siegler; Joe G N Garcia; Jeffrey R Jacobson Journal: Am J Respir Cell Mol Biol Date: 2014-02 Impact factor: 6.914
Authors: Jordan M Thompson; Alejandro Alvarez; Monika K Singha; Matthew W Pavesic; Quy H Nguyen; Luke J Nelson; David A Fruman; Olga V Razorenova Journal: Mol Cancer Ther Date: 2018-05-02 Impact factor: 6.261
Authors: Phoebe A Stapleton; Adam G Goodwill; Milinda E James; Robert W Brock; Jefferson C Frisbee Journal: J Inflamm (Lond) Date: 2010-11-18 Impact factor: 4.981
Authors: John McCracken; Andrea Baccarelli; Mirjam Hoxha; Laura Dioni; Steve Melly; Brent Coull; Helen Suh; Pantel Vokonas; Joel Schwartz Journal: Environ Health Perspect Date: 2010-11 Impact factor: 9.031